CN113242859B - 吡咯并嘧啶化合物的治疗用途及其固体药物组合物 - Google Patents

吡咯并嘧啶化合物的治疗用途及其固体药物组合物 Download PDF

Info

Publication number
CN113242859B
CN113242859B CN201980081492.2A CN201980081492A CN113242859B CN 113242859 B CN113242859 B CN 113242859B CN 201980081492 A CN201980081492 A CN 201980081492A CN 113242859 B CN113242859 B CN 113242859B
Authority
CN
China
Prior art keywords
pharmaceutical composition
solid pharmaceutical
compound
formula
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980081492.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN113242859A (zh
Inventor
王栋
李清侠
戴峻
李晨
江竹莲
孙艳清
陈晶晶
金玲玲
刘君动
李其德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Pharmaceutical Holdings Beijing Co ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Shouyao Holdings Beijing Co Ltd filed Critical Capital Pharmaceutical Holdings Beijing Co ltd
Priority to CN202310447777.1A priority Critical patent/CN116473973A/zh
Publication of CN113242859A publication Critical patent/CN113242859A/zh
Application granted granted Critical
Publication of CN113242859B publication Critical patent/CN113242859B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980081492.2A 2018-12-24 2019-12-24 吡咯并嘧啶化合物的治疗用途及其固体药物组合物 Active CN113242859B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310447777.1A CN116473973A (zh) 2018-12-24 2019-12-24 吡咯并嘧啶化合物的治疗用途及其固体药物组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018115818158 2018-12-24
CN201811581815 2018-12-24
CN201910679429 2019-07-26
CN2019106794290 2019-07-26
PCT/CN2019/127837 WO2020135401A1 (zh) 2018-12-24 2019-12-24 吡咯并嘧啶化合物的治疗用途及其固体药物组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310447777.1A Division CN116473973A (zh) 2018-12-24 2019-12-24 吡咯并嘧啶化合物的治疗用途及其固体药物组合物

Publications (2)

Publication Number Publication Date
CN113242859A CN113242859A (zh) 2021-08-10
CN113242859B true CN113242859B (zh) 2023-04-14

Family

ID=71126879

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980081492.2A Active CN113242859B (zh) 2018-12-24 2019-12-24 吡咯并嘧啶化合物的治疗用途及其固体药物组合物
CN202310447777.1A Pending CN116473973A (zh) 2018-12-24 2019-12-24 吡咯并嘧啶化合物的治疗用途及其固体药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310447777.1A Pending CN116473973A (zh) 2018-12-24 2019-12-24 吡咯并嘧啶化合物的治疗用途及其固体药物组合物

Country Status (8)

Country Link
US (1) US20220072002A1 (enExample)
EP (1) EP3904356A4 (enExample)
JP (2) JP2022515272A (enExample)
KR (1) KR20210132007A (enExample)
CN (2) CN113242859B (enExample)
AU (1) AU2019413421B9 (enExample)
CA (1) CA3123985A1 (enExample)
WO (1) WO2020135401A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548855A (ja) * 2020-11-05 2023-11-21 エグゼリクシス， インコーポレイテッド キナーゼ阻害剤の医薬組成物
CN118973582A (zh) * 2022-03-21 2024-11-15 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物治疗中高危骨髓纤维化的用途
WO2024153148A1 (zh) * 2023-01-18 2024-07-25 北京普祺医药科技股份有限公司 一种杂环化合物、药物组合物及其用途
WO2024230727A1 (zh) * 2023-05-09 2024-11-14 正大天晴药业集团股份有限公司 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0775204A1 (en) * 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
PL351069A1 (en) * 1999-12-08 2003-03-10 Pharmacia Corp Valdecoxib compositions
US20070054848A1 (en) * 2003-03-28 2007-03-08 Masaya Tohyama Composition and method for nerve regeneration
US20050130302A1 (en) * 2003-09-29 2005-06-16 Reprocell Inc. Method and composition for regulating expansion of stem cells
WO2007089926A2 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
KR101566840B1 (ko) * 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
AR076794A1 (es) * 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
EP3354652B1 (en) * 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PH12013502523A1 (en) * 2011-06-14 2019-10-11 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
NZ714502A (en) * 2011-07-05 2017-04-28 Vertex Pharma Processes and intermediates for producing azaindoles
CN104418858B (zh) * 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
CN103585126A (zh) * 2013-11-18 2014-02-19 南京艾德凯腾生物医药有限责任公司 一种托法替尼组合物及制备方法
NZ723859A (en) * 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
AU2015276857B2 (en) * 2014-06-20 2017-10-19 Vaxart, Inc. Anhydrous crystalline free base form of-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
CN105777754B (zh) * 2014-12-16 2019-07-26 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物
KR101964546B1 (ko) * 2015-07-27 2019-04-01 유니켐 레버러토리스 리미티드 토파시티닙 경구 붕해 정제
CN108368115B (zh) * 2015-12-15 2020-01-03 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的盐
CN107334738B (zh) * 2016-04-28 2021-02-09 天津科伦药物研究有限公司 一种含巴瑞克替尼的药物组合物及其制备方法和用途
CN107759600A (zh) 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
CN107513069A (zh) * 2016-06-16 2017-12-26 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法
CN107513067A (zh) * 2016-06-16 2017-12-26 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物
HRP20240112T1 (hr) * 2017-03-14 2024-04-12 Galapagos Nv Farmaceutske tvari koje uključuju inhibitor janus kinaze (jak)
WO2018204787A1 (en) * 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
US12447154B2 (en) * 2020-03-09 2025-10-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrrolopyrimidine compound for treating hemophagocytic syndrome
CA3222218A1 (en) * 2021-06-21 2022-12-29 Lifan TU Use of pyrrolopyrimidine compound and pharmaceutical composition thereof for treating chronic graft versus host disease

Also Published As

Publication number Publication date
CA3123985A1 (en) 2020-07-02
US20220072002A1 (en) 2022-03-10
EP3904356A1 (en) 2021-11-03
CN116473973A (zh) 2023-07-25
WO2020135401A1 (zh) 2020-07-02
JP2022515272A (ja) 2022-02-17
AU2019413421B2 (en) 2025-02-13
KR20210132007A (ko) 2021-11-03
JP2025032127A (ja) 2025-03-11
AU2019413421A1 (en) 2021-08-12
AU2019413421B9 (en) 2025-02-20
EP3904356A4 (en) 2022-09-21
CN113242859A (zh) 2021-08-10

Similar Documents

Publication Publication Date Title
US20240293406A1 (en) Compositions and methods for treating myelofibrosis
AU2024203642B2 (en) Methods of treating Crohn's disease and ulcerative colitis
CN113242859B (zh) 吡咯并嘧啶化合物的治疗用途及其固体药物组合物
US20190269671A1 (en) Method for treating tumour, pharmaceutical composition and medicinal kit
CN110809471A (zh) 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
US9907795B2 (en) Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
TW202423445A (zh) 英菲格拉替尼在治療胃癌和腺癌中的用途
HK40055927B (en) Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
HK40055927A (en) Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
RU2810112C2 (ru) Лечебное применение пирролопиримидинового соединения и твердая фармацевтическая композиция пирролопиримидинового соединения
HK40063616A (en) Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
AU2020386903A1 (en) Dosing regimens for a protein kinase C inhibitor
TW202245786A (zh) 喹唑啉化合物及藥物組合物的應用
KR20250095627A (ko) 에스트로겐 수용체-매개 장애의 치료 방법
CA3269490A1 (en) Methods of treating estrogen receptor-mediated disorders
HK1189177A (en) Compositions for treating myelofibrosis
HK1189177B (en) Compositions for treating myelofibrosis
OA17692A (en) Compositions and methods for treating myelofibrosis.
EA052710B1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Applicant after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Applicant before: Shouyao holding (Beijing) Co.,Ltd.

CB02 Change of applicant information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40055927

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20260408

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Country or region after: China

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Country or region before: China

Patentee before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Patentee before: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd.